News
Low disease state for childhood lupus approaches validation
A new childhood version of the Lupus Low Disease Activity State has been purposefully developed to align with the criteria already used for adults...
News
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
In about 5% of patients with seropositive RA, C-reactive protein levels were normal despite disease flares during a 5-year period. The findings...
News
Long-COVID rate may be higher with rheumatic diseases
The results highlight the need for close monitoring and optimized multidisciplinary care for long-term adverse events after COVID-19 in patients...
News
NSAID use may mask MRI findings in a quarter of spondyloarthritis cases
Among nearly one in four patients whose MRI results were initially positive for sacroiliitis, results were negative 6 weeks after NSAIDs were...
News
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
News
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritis
There is no difference in the risk of myocardial infarction with interleukin-6 (IL-6) vs. anti–tumor necrosis factor (TNF) therapy for rheumatoid...
News
Cardiovascular risk score multipliers suggested for rheumatic diseases
Guidelines could tailor cardiovascular risk scores by using a multiplier of 2.5 for systemic sclerosis, 2.0 for lupus, and 1.5 for any other...
News
RA risk raised by work-related inhaled agents
Exposure to detergents, dusts, and other chemicals in the workplace could be putting genetically susceptible people at risk of rheumatoid...
News
Gestational hypertension-diabetes combo signals CVD risk
Having both hypertensive disorders and diabetes while pregnant ups later cardiovascular risk, suggesting greater care is needed when these...
News
Rituximab raises remission rate in granulomatosis with polyangiitis
Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target...
News
52-week data show lebrikizumab atopic dermatitis effects maintained
ADvocate1 and ADvocate2 are two of several phase 3 trials evaluating the efficacy and safety of lebrikizumab for the treatment of atopic...
News
Ruxolitinib repigments many vitiligo-affected body areas
Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.
News
BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported
Treatment with the oral JAK inhibitor was significantly more effective than placebo only with the highest dose evaluated.
News
Alopecia areata: Positive results reported for two investigational JAK inhibitors
“This is truly transformative therapy,” one of the investigators, Brett King, MD, PhD, said.
News
Study identifies skin biomarkers that predict newborn eczema risk
"We are able to identify predictive immune biomarkers of atopic dermatitis using a noninvasive method," the investigator said.